Why a Passing COA Isn't Enough: Lessons From a Quality Inspector on Lonza, LIMS, and Pharma Supply

Let me start with a scene from a review I did in Q1 2024. A chemical supplier sent us a batch release certificate. The certificate of analysis, or COA, said everything was within specification. The pH result looked fine. The assay looked fine. But when I pulled the raw data behind that COA, the numbers did not match the analytical method that was referenced. The supplier was not trying to hide anything. They simply did not have a system that connected the summary document to the original test files. I rejected the batch anyway.

I have spent the last four years reviewing quality documents for pharma and chemical purchases. Roughly 200 to 250 COAs and batch records per year, depending on how you count. I have seen enough to be skeptical of clean-looking reports.

The Surface Problem: A COA Says Pass, But the Batch Fails

This is not a consumer product situation. I am not going to tell you about Gorilla Clear Grip contact adhesive and how to stick something together in ten minutes. In pharmaceutical manufacturing, a batch that looks fine can contaminate a production line or fail a stability test months later. By then, the product is already in the warehouse or in patients. The cost of that is not a trip to the hardware store. It is a recall, an audit finding, or worse.

When a material arrives and does not behave the way it should, the first instinct is to blame the product. But in my experience, most release failures start long before the truck shows up. They start in the quality system. The question is not whether the sample passed. The question is whether the result can be verified.

The Real Problem Is the Data Trail, Not the Test Result

What I mean is, a COA is a snapshot. It says at this time, with this method, on this sample, these were the results. A snapshot does not show who ran the test, when it was run, which instrument was used, or whether the method was followed exactly. That evidence lives in the LIMS.

If you have typed what is LIMS in pharma into a search engine, here is the practical definition: a LIMS, or Laboratory Information Management System, is the software that tracks samples, test methods, instruments, raw data, and final results in a laboratory. In pharma, it is the backbone of data integrity. A well-configured LIMS creates an audit trail. Every time someone looks at a result, edits a file, or runs a sample, the system records it. That means the COA is no longer a piece of paper someone types. It is a view into a database that does not forget.

Why does this matter? Because the cost of a failed batch is usually not the failed batch. It is the delay, the rework, and the lost trust. And those costs multiply when the data trail is incomplete.

For pharma HCPs that are involved in supplier review, the LIMS question is a useful shortcut. You do not have to visit every factory. You just have to ask for an example of a raw data trace. If the supplier cannot produce it, the problem is not the missing file. The problem is the quality culture.

What a Missing Audit Trail Actually Costs

In March 2023, I had a vendor who couldn't produce raw data for a release test. The batch sat in quarantine for 11 days. The production line that depended on it had to be idled, and the final product release slipped by almost six weeks. The direct cost of that delay was around $38,000 in rework and idle labor. That does not include the cost of telling the customer we would be late. It took that experience for me to understand that a small premium for reliable documentation is actually a time certainty hedge. When a deadline matters, uncertain cheap is more expensive than certain and slightly more expensive.

I still kick myself for not insisting on LIMS access before signing our last supply agreement. If I had asked for it earlier, we would have found the data gap in a few hours instead of eleven days.

Regulators ask the same questions. Under 21 CFR Part 11, electronic records must have controlled access, secure audit trails, and defined retention. ICH Q7, the guidance for API manufacturing, also expects records to be reliable and traceable. An inspector from FDA, EMA, or MHRA can ask for the raw data behind any result. If the supplier cannot show it, the batch is suspect. That is not a theoretical risk. It is the reality for every pharma HCP or quality professional who signs off on a supplier.

What I Now Look For Before I Approve a Supplier

First, I stop asking whether a batch passed. I ask how I know. If the evidence is only a PDF summary, that is not enough. I want to see the system that produced the summary.

Second, I make LIMS access part of the contract. I want the ability to see the audit trail, even if I rarely use it. The point is not to spy on the supplier. The point is to confirm that the quality system is real.

Third, I budget for certainty. When a production line is waiting, and a wrong material can stop everything, I will pay more for a supplier that can show me the full story before the material ships. That is the time certainty premium. I used to think of it as an unneeded cost. Now I think of it as the cheapest insurance in the supply chain.

When I look at a supplier like Lonza, the first thing that stands out is not a single product. It is the system around the product. If you have a Lonza login, you can see why. The customer portal gives you access to batch certificates, testing documentation, and the kind of traceability that makes an audit easier. It tells me that Lonza Chemicals, or any other division, does not treat quality documents as an afterthought.

Lonza will not always be the cheapest option on every SKU. I do not expect them to be. I expect consistency, traceability, and an honest audit path. Spend twenty minutes clicking through the documentation for one batch. That is worth more than any sales presentation.

Next time someone asks what is LIMS in pharma, do not just say laboratory information management system. Say it is the difference between a claim and proof. A COA tells you that a batch was good. The data trail tells you why that statement deserves to be trusted. In pharma, that difference is not academic. It is the difference between a clean release and a very expensive surprise.